A prospective, multicenter phase 2 trial evaluated the safety of neoadjuvant radiation plus immunotherapy before radical cystectomy for bladder cancer.

编者按：2026年欧洲肿瘤内科学会乳腺癌大会（ESMO BC）将于5月6日至8日在德国柏林举行，本届大会将覆盖乳腺癌的靶向治疗、内分泌治疗及免疫治疗等前沿领域，并公布多项重磅研究成果，亮点纷呈。近年来，中国乳腺癌领域进展迅速，本届大会中共有64项研究入选，凸显了中国研究的国际影响力。《肿瘤瞭望》特对大会中中国专家的口头报告（2项）和壁报（62项）题目进行汇总，以供读者参考，如有缺漏或错误，欢迎指正 ...

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

Event-driven primary disease-free survival (“DFS”) analysis for Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”) is anticipated in 1H 2026 ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced the publication of the PREDICT-DNA study in the Journal of Clinical Oncology. The article, "The ...

Data show T-DXd improves invasive disease-free survival and reduces the risk of distant recurrence in early HER2-positive breast cancer.

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Co-occurring alterations in EGFR-mutant NSCLC are increasingly detected via broad NGS and may signal aggressive biology, prompting interest in escalation strategies that address concurrent drivers.

In today's Pharmaceutical Executive Daily, the FDA approves leucovorin as the first-ever treatment for an ultra-rare genetic condition called cerebral folate transport deficiency, Enhertu receives FDA ...

FDA granted Priority Review to AstraZeneca’s supplemental application for Enhertu in early-stage HER2-positive breast cancer, moving the drug closer to a potential new indication for patients at high ...

US FDA accepts and grants priority review status to AstraZeneca and Daiichi Sankyo’s sBLA for Enhertu to treat adult patients with HER2-positive early breast cancer: Cambridge, ...

The firms submitted data from the Phase III DESTINY-Breast05 trial comparing Enhertu to Roche's antibody-drug conjugate Kadcyla.